GLP-1 Receptor Agonists: Usage Trends, Spending Impact, and Access Challenges

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment landscape for type 2 diabetes and obesity in recent years. Once reserved for patients with inadequate glycemic control on oral medications, these injectable drugs are now widely prescribed for weight management and cardiovascular risk reduction. As their clinical benefits have become more evident, utilization has surged—driving significant increases in prescription drug spending across public and private payers. However, despite their proven efficacy, inconsistent insurance coverage and high out-of-pocket costs remain major barriers to widespread access. This article examines the latest trends in GLP-1 RA use, their impact on healthcare expenditures, and ongoing efforts to improve affordability and equity in access.

Rapid Growth in GLP-1 RA Prescriptions

Prescriptions for GLP-1 receptor agonists have increased dramatically since the approval of semaglutide (Wegovy) for chronic weight management in 2021. According to IQVIA data, U.S. Prescriptions for GLP-1 RAs grew from approximately 5.2 million in 2020 to over 18.4 million in 2023—a more than threefold increase in just three years. This surge reflects expanded indications, growing awareness of obesity as a chronic disease, and strong patient demand fueled by social media and celebrity endorsements.

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist—have been key drivers of this growth. In 2023 alone, Wegovy accounted for over 40% of new obesity pharmacotherapy prescriptions, whereas Mounjaro saw rapid uptake for both diabetes and off-label weight loss use prior to its Zepbound approval for obesity.

These medications work by mimicking incretin hormones that regulate appetite, gradual gastric emptying, and enhance glucose-dependent insulin secretion. Clinical trials have demonstrated average weight losses of 15% to 22% with higher-dose semaglutide and tirzepatide, alongside improvements in blood pressure, lipid profiles, and cardiovascular outcomes.

Impact on Prescription Drug Spending

The rapid adoption of GLP-1 RAs has contributed significantly to rising prescription drug expenditures. A 2024 analysis by the Kaiser Family Foundation (KFF) found that spending on GLP-1 receptor agonists increased by 1,200% between 2020 and 2023, reaching an estimated $22.6 billion in U.S. Retail drug costs in 2023. This made GLP-1 RAs the third-highest spending therapeutic class, behind only insulin, and antivirals.

Private insurers and Medicare Part D plans have absorbed much of this cost. In 2023, GLP-1 RA spending accounted for approximately 6.5% of total Part D drug expenditures, up from less than 1% in 2020. The Congressional Budget Office (CBO) projects that if current trends continue, annual spending on obesity medications could exceed $50 billion by 2030, largely driven by GLP-1 and dual GIP/GLP-1 agonists.

While these costs are substantial, proponents argue that long-term savings from reduced diabetes complications, cardiovascular events, and obesity-related comorbidities may offset initial expenditures. A 2023 modeling study published in JAMA Health Forum estimated that widespread use of semaglutide for obesity prevention could save the U.S. Healthcare system $245 billion over 10 years by preventing diabetes, heart disease, and certain cancers.

Persistent Barriers to Coverage and Access

Despite clinical effectiveness, access to GLP-1 RAs remains uneven due to restrictive formularies, prior authorization requirements, and high list prices. The average wholesale price (AWP) for a monthly supply of Wegovy is approximately $1,350, while Mounjaro and Zepbound list for over $1,000 per month without insurance.

Many private insurers impose strict criteria for coverage, often requiring documentation of failed attempts with lifestyle interventions or lower-cost medications before approving GLP-1 RA therapy. Medicare Part D plans are prohibited by law from covering drugs for weight loss alone, although they may cover GLP-1 RAs when prescribed for type 2 diabetes or cardiovascular risk reduction.

Medicaid coverage varies widely by state. As of 2024, fewer than 20 state Medicaid programs provide routine coverage for anti-obesity medications, including GLP-1 RAs, leaving low-income populations disproportionately affected. This disparity raises concerns about health equity, particularly given the higher prevalence of obesity in underserved communities.

Manufacturer savings programs and copay cards offer temporary relief for commercially insured patients, but these do not apply to government beneficiaries and are often unavailable to those with high-deductible health plans or no insurance.

Strategies to Improve Access and Affordability

Policymakers, employers, and healthcare systems are exploring multiple strategies to address access barriers:

• Value-based pricing models: Some insurers are experimenting with outcomes-based contracts that tie reimbursement to measurable health improvements, such as weight loss milestones or reduced hospitalization rates.
• Employer-sponsored wellness programs: Large employers are increasingly adding GLP-1 RAs to their formularies as part of comprehensive obesity management programs, recognizing the potential for reduced absenteeism and healthcare costs.
• Legislative action: Bills such as the Treat and Reduce Obesity Act (TROA), which would allow Medicare Part D to cover FDA-approved obesity medications, have gained bipartisan support but remain stalled in Congress.
• Generic and biosimilar competition: While no generic GLP-1 RAs are currently available, patent expirations beginning in the mid-2030s may eventually lower costs. In the interim, compounded versions of semaglutide have emerged, though the FDA warns against their use due to safety and potency concerns.
• Primary care integration: Expanding obesity screening and treatment training for primary care providers could improve appropriate prescribing and reduce reliance on specialists, thereby increasing access in underserved areas.

Future Outlook

The GLP-1 RA market is poised for continued growth, with several next-generation agents in development. These include triple-hormone agonists targeting GLP-1, GIP, and glucagon receptors, which may offer even greater weight loss and metabolic benefits. Oral formulations of semaglutide (already approved for diabetes) and other GLP-1 RAs are also advancing through clinical trials, potentially improving adherence and convenience.

As evidence accumulates on the long-term benefits of these medications—not only for diabetes and obesity but also for heart failure, kidney disease, and neurodegenerative conditions—pressure is mounting to reevaluate coverage policies. Stakeholders agree that sustainable access will require balancing innovation incentives with affordability, ensuring that breakthrough therapies reach the patients who necessitate them most.

Key Takeaways

• GLP-1 receptor agonist prescriptions have increased over 350% since 2020, driven by expanded use for obesity and cardiovascular risk reduction.
• Spending on these drugs reached $22.6 billion in 2023, making them one of the top cost drivers in prescription drug expenditures.
• Despite proven benefits, access is limited by high costs, restrictive insurance policies, and exclusion of obesity treatment from Medicare Part D coverage.
• Strategies to improve access include value-based contracting, employer wellness programs, legislative reform, and future generic competition.
• Ongoing research into oral formulations and multi-receptor agonists may further expand the role of GLP-1-based therapies in chronic disease management.

Frequently Asked Questions (FAQ)

Are GLP-1 receptor agonists safe for long-term use?

Long-term safety data are still being collected, but current evidence from trials lasting up to four years shows a favorable safety profile. The most common side effects are gastrointestinal—such as nausea, vomiting, and diarrhea—which tend to be transient. Rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in rodent studies; relevance to humans remains uncertain).

Can I take a GLP-1 RA if I don’t have diabetes?

Yes. Medications like Wegovy and Zepbound are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, such as hypertension or dyslipidemia, regardless of diabetes status.

Why won’t my insurance cover a GLP-1 RA for weight loss?

Many insurance plans, including Medicare Part D, do not cover medications prescribed solely for weight loss due to historical exclusion policies. Coverage is more likely when the drug is prescribed for type 2 diabetes, heart failure, or kidney disease—indications that are explicitly covered under most plans.

Are there cheaper alternatives to brand-name GLP-1 RAs?

Currently, there are no generic versions of semaglutide, tirzepatide, or other GLP-1 RAs available in the U.S. Some patients use lower-dose formulations approved for diabetes (e.g., Ozempic for weight loss), but this is considered off-label and may not be covered by insurance. Compounded versions exist but are not FDA-approved and carry safety risks.

Will the cost of GLP-1 RAs go down in the future?

Prices may decrease after patent expirations, which begin around 2032 for semaglutide and 2036 for tirzepatide. Until then, cost-reliance on manufacturer assistance programs, employer coverage, and potential policy changes will be key to improving affordability.